{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:13:45Z","timestamp":1783469625479,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Research Ward Excellence Program","award":["BRWEP2024W134080103"],"award-info":[{"award-number":["BRWEP2024W134080103"]}]},{"name":"National Key Research and Development Plan of China","award":["2021YFA1100902"],"award-info":[{"award-number":["2021YFA1100902"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370160"],"award-info":[{"award-number":["82370160"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015083","name":"Peking University People\u2019s Hospital","doi-asserted-by":"publisher","award":["RZ2024-01"],"award-info":[{"award-number":["RZ2024-01"]}],"id":[{"id":"10.13039\/501100015083","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Joint Research Project of the Shijiazhuang-Peking University Cooperation Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02172-w","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:25:22Z","timestamp":1778682322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ultra-Low BCR::ABL1 positivity by digital PCR does not improve post-transplant risk stratification beyond real-time PCR in Ph+ acute lymphoblastic leukemia post-transplant"],"prefix":"10.1007","volume":"26","author":[{"given":"Ya","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Su","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Zhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2172_CR1","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2023020794","volume":"143","author":"N Gokbuget","year":"2024","unstructured":"Gokbuget N, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143:1891\u2013902. https:\/\/doi.org\/10.1182\/blood.2023020794.","journal-title":"Blood"},{"key":"2172_CR2","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/ajh.27708","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Jabbour E. Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2025;100:1205\u201331. https:\/\/doi.org\/10.1002\/ajh.27708.","journal-title":"Am J Hematol"},{"key":"2172_CR3","doi-asserted-by":"publisher","first-page":"900","DOI":"10.21147\/j.issn.1000-9604.2025.06.03","volume":"37","author":"L Hu","year":"2025","unstructured":"Hu L, Xia Y, Huang X. Leukemia epidemiology in China: burden, trends, and determinants in the 21st century. Chin J Cancer Res. 2025;37:900\u201311. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.06.03.","journal-title":"Chin J Cancer Res"},{"key":"2172_CR4","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2023023568","volume":"143","author":"N Gokbuget","year":"2024","unstructured":"Gokbuget N, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143:1903\u201330. https:\/\/doi.org\/10.1182\/blood.2023023568.","journal-title":"Blood"},{"key":"2172_CR5","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2013-11-538728","volume":"123","author":"S Mizuta","year":"2014","unstructured":"Mizuta S, et al. Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2014;123:2325\u201332. https:\/\/doi.org\/10.1182\/blood-2013-11-538728.","journal-title":"Blood"},{"key":"2172_CR6","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s11912-025-01683-1","volume":"27","author":"V Agrawal","year":"2025","unstructured":"Agrawal V, Koller P, Stein A, Pullarkat V, Aldoss I. The role of transplant for Philadelphia-positive B-cell acute lymphoblastic leukemia in 2025. Curr Oncol Rep. 2025;27:748\u201360. https:\/\/doi.org\/10.1007\/s11912-025-01683-1.","journal-title":"Curr Oncol Rep"},{"key":"2172_CR7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.bbmt.2015.02.009","volume":"21","author":"H Chen","year":"2015","unstructured":"Chen H, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2015;21:1110\u20136. https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.009.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2172_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.leukres.2017.05.021","volume":"59","author":"H Chen","year":"2017","unstructured":"Chen H, et al. Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. Leuk Res. 2017;59:136\u201341. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.021.","journal-title":"Leuk Res"},{"key":"2172_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bbmt.2017.12.777","volume":"24","author":"J Wang","year":"2018","unstructured":"Wang J, et al. Allogeneic stem cell transplantation versus tyrosine kinase inhibitors combined with chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24:741\u201350. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.777.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2172_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106930","volume":"121","author":"H Chen","year":"2022","unstructured":"Chen H, et al. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation. Leuk Res. 2022;121:106930. https:\/\/doi.org\/10.1016\/j.leukres.2022.106930.","journal-title":"Leuk Res"},{"key":"2172_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02698-9","author":"H Chen","year":"2025","unstructured":"Chen H, et al. Long-term survival in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation: a single-center experience. Bone Marrow Transplant. 2025. https:\/\/doi.org\/10.1038\/s41409-025-02698-9.","journal-title":"Bone Marrow Transplant"},{"key":"2172_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00277-025-06198-0","volume":"104","author":"J Kong","year":"2025","unstructured":"Kong J, et al. Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol. 2025;104:801\u20138. https:\/\/doi.org\/10.1007\/s00277-025-06198-0.","journal-title":"Ann Hematol"},{"key":"2172_CR13","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/jco.24.00108","volume":"42","author":"R Kim","year":"2024","unstructured":"Kim R, et al. Significance of measurable residual disease in adult Philadelphia chromosome-positive ALL: A GRAAPH-2014 study. J Clin Oncol. 2024;42:3140\u201350. https:\/\/doi.org\/10.1200\/jco.24.00108.","journal-title":"J Clin Oncol"},{"key":"2172_CR14","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/ajh.26949","volume":"98","author":"NJ Short","year":"2023","unstructured":"Short NJ, et al. Ultrasensitive NGS MRD assessment in Ph\u2009+\u2009ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023;98:1196\u2013203. https:\/\/doi.org\/10.1002\/ajh.26949.","journal-title":"Am J Hematol"},{"key":"2172_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00320","volume":"10","author":"SQ Li","year":"2020","unstructured":"Li SQ, et al. Different effects of pre-transplantation measurable residual disease on outcomes according to transplant modality in patients with Philadelphia chromosome positive ALL. Front Oncol. 2020;10:320. https:\/\/doi.org\/10.3389\/fonc.2020.00320.","journal-title":"Front Oncol"},{"key":"2172_CR16","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.bbmt.2018.12.007","volume":"25","author":"YJ Xue","year":"2019","unstructured":"Xue YJ, et al. Allogeneic hematopoietic stem cell transplantation, especially haploidentical, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant. 2019;25:1611\u201320. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.007.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2172_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40779-025-00640-0","volume":"12","author":"LQ Cao","year":"2025","unstructured":"Cao LQ, et al. Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study. Mil Med Res. 2025;12:63. https:\/\/doi.org\/10.1186\/s40779-025-00640-0.","journal-title":"Mil Med Res"},{"key":"2172_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164112","author":"E Abruzzese","year":"2023","unstructured":"Abruzzese E, et al. Minimal residual disease detection at RNA and leukemic stem cell (LSC) levels: Comparison of RT-qPCR, d-PCR and CD26\u2009+\u2009stem cell measurements in chronic myeloid leukemia (CML) patients in deep molecular response (DMR). Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15164112.","journal-title":"Cancers"},{"key":"2172_CR19","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/s41375-022-01612-2","volume":"36","author":"M Salmon","year":"2022","unstructured":"Salmon M, et al. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia. 2022;36:1879\u201386. https:\/\/doi.org\/10.1038\/s41375-022-01612-2.","journal-title":"Leukemia"},{"key":"2172_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jmoldx.2013.04.007","volume":"15","author":"RD Press","year":"2013","unstructured":"Press RD, Kamel-Reid S, Ang D. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia. J Mol Diagn. 2013;15:565\u201376. https:\/\/doi.org\/10.1016\/j.jmoldx.2013.04.007.","journal-title":"J Mol Diagn"},{"key":"2172_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/jclinpath-2015-203538","volume":"69","author":"S Latham","year":"2016","unstructured":"Latham S, et al. BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia. J Clin Pathol. 2016;69:817\u201321. https:\/\/doi.org\/10.1136\/jclinpath-2015-203538.","journal-title":"J Clin Pathol"},{"key":"2172_CR22","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","volume":"125","author":"D Selimoglu-Buet","year":"2015","unstructured":"Selimoglu-Buet D, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015;125:3618\u201326. https:\/\/doi.org\/10.1182\/blood-2015-01-620781.","journal-title":"Blood"},{"key":"2172_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12967-019-02194-x","volume":"18","author":"R Alves","year":"2020","unstructured":"Alves R, et al. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-\u03b1. J Transl Med. 2020;18:2. https:\/\/doi.org\/10.1186\/s12967-019-02194-x.","journal-title":"J Transl Med"},{"key":"2172_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052116","author":"AP de Azambuja","year":"2025","unstructured":"de Azambuja AP, et al. Comprehensive analysis of high-sensitive flow cytometry and molecular mensurable residual disease in Philadelphia Chromosome-Positive acute leukemia. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26052116.","journal-title":"Int J Mol Sci"},{"key":"2172_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3343\/alm.2020.40.1.72","volume":"40","author":"HJ Chung","year":"2020","unstructured":"Chung HJ, et al. Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay. Ann Lab Med. 2020;40:72\u20135. https:\/\/doi.org\/10.3343\/alm.2020.40.1.72.","journal-title":"Ann Lab Med"},{"key":"2172_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/ejh.13084","volume":"101","author":"WJ Wang","year":"2018","unstructured":"Wang WJ, et al. Droplet digital PCR for BCR\/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression. Eur J Haematol. 2018;101:291\u20136. https:\/\/doi.org\/10.1111\/ejh.13084.","journal-title":"Eur J Haematol"},{"key":"2172_CR27","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/cam4.2087","volume":"8","author":"S Bernardi","year":"2019","unstructured":"Bernardi S, et al. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med. 2019;8:2041\u201355. https:\/\/doi.org\/10.1002\/cam4.2087.","journal-title":"Cancer Med"},{"key":"2172_CR28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori S, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90:910\u20134. https:\/\/doi.org\/10.1002\/ajh.24120.","journal-title":"Am J Hematol"},{"key":"2172_CR29","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1039\/d4lc00175c","volume":"24","author":"W Wei","year":"2024","unstructured":"Wei W, et al. Analytical validation of the DropXpert S6 system for diagnosis of chronic myelocytic leukemia. Lab Chip. 2024;24:3080\u201392. https:\/\/doi.org\/10.1039\/d4lc00175c.","journal-title":"Lab Chip"},{"key":"2172_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"XH Zhang","year":"2021","unstructured":"Zhang XH, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14:145. https:\/\/doi.org\/10.1186\/s13045-021-01159-2.","journal-title":"J Hematol Oncol"},{"key":"2172_CR31","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, et al. Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17:2318\u201357. https:\/\/doi.org\/10.1038\/sj.leu.2403135.","journal-title":"Leukemia"},{"key":"2172_CR32","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia. 2003;17:2474\u201386. https:\/\/doi.org\/10.1038\/sj.leu.2403136.","journal-title":"Leukemia"},{"key":"2172_CR33","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1021\/ac202028g","volume":"83","author":"BJ Hindson","year":"2011","unstructured":"Hindson BJ, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83:8604\u201310. https:\/\/doi.org\/10.1021\/ac202028g.","journal-title":"Anal Chem"},{"key":"2172_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett. 2024;605:217264. https:\/\/doi.org\/10.1016\/j.canlet.2024.217264.","journal-title":"Cancer Lett"},{"key":"2172_CR35","doi-asserted-by":"crossref","unstructured":"Heuser M. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138, 2753\u20132767 (2021).","DOI":"10.1182\/blood.2021013626"},{"key":"2172_CR36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3518","volume":"146","author":"Y Luo","year":"2025","unstructured":"Luo Y, et al. Droplet digital PCR improves measurable residual disease detection and predicts relapse in KMT2A-rearranged leukemia after allogeneic hematopoietic stem cell transplantation: a prospective study. Blood. 2025;146:3518. https:\/\/doi.org\/10.1182\/blood-2025-3518.","journal-title":"Blood"},{"key":"2172_CR37","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jmoldx.2022.04.013","volume":"24","author":"C Schwinghammer","year":"2022","unstructured":"Schwinghammer C, et al. A new view on minimal residual disease quantification in acute lymphoblastic leukemia using droplet digital PCR. J Mol Diagn. 2022;24:856\u201366. https:\/\/doi.org\/10.1016\/j.jmoldx.2022.04.013.","journal-title":"J Mol Diagn"},{"key":"2172_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2023.100373","volume":"4","author":"M Lv","year":"2023","unstructured":"Lv M, Shen M, Mo X. Development of allogeneic hematopoietic stem cell transplantation in 2022: regenerating \u201cGroot\u201d to heal the world. Innovation (Camb). 2023;4:100373. https:\/\/doi.org\/10.1016\/j.xinn.2023.100373.","journal-title":"Innovation (Camb)"},{"key":"2172_CR39","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41423-023-01007-y","volume":"20","author":"M Lv","year":"2023","unstructured":"Lv M, Guo HD, Huang XJ. A perfect mismatch: haploidentical hematopoietic stem cell transplantation overtakes a bend. Cell Mol Immunol. 2023;20:978\u201380. https:\/\/doi.org\/10.1038\/s41423-023-01007-y.","journal-title":"Cell Mol Immunol"},{"key":"2172_CR40","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3760\/cma.j.issn.0253-2727.2023.11.004","volume":"44","author":"HL Gao","year":"2023","unstructured":"Gao HL, et al. Comparison of BCR::ABL (P210) mRNA levels detected by dPCR and qPCR methods in patients with chronic myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2023;44:906\u201310. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.11.004.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2172_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110431","volume":"9","author":"Y Jing","year":"2014","unstructured":"Jing Y, et al. Susceptibility of Ph-positive ALL to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis. PLoS One. 2014;9:e110431. https:\/\/doi.org\/10.1371\/journal.pone.0110431.","journal-title":"PLoS One"},{"key":"2172_CR42","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288671","author":"A Rubio-San-Simon","year":"2025","unstructured":"Rubio-San-Simon A, et al. Two episodes of Ph+ acute leukemia with divergent Ig\/TCR rearrangements in two patients with persistent BCR::ABL1 positivity: a 17-year follow-up. Haematologica. 2025. https:\/\/doi.org\/10.3324\/haematol.2025.288671.","journal-title":"Haematologica"},{"key":"2172_CR43","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","volume":"36","author":"J Zuna","year":"2022","unstructured":"Zuna J, et al. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia. 2022;36:2793\u2013801. https:\/\/doi.org\/10.1038\/s41375-022-01668-0.","journal-title":"Leukemia"},{"key":"2172_CR44","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s11427-024-2666-8","volume":"67","author":"X Mo","year":"2024","unstructured":"Mo X, et al. Single-cell immune landscape of measurable residual disease in acute myeloid leukemia. Sci China Life Sci. 2024;67:2309\u201322. https:\/\/doi.org\/10.1007\/s11427-024-2666-8.","journal-title":"Sci China Life Sci"},{"key":"2172_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1515\/jtim-2025-0028","volume":"13","author":"S Fan","year":"2025","unstructured":"Fan S, et al. Artificial intelligence-based predictive model for relapse in acute myeloid leukemia patients following haploidentical hematopoietic cell transplantation. J Transl Int Med. 2025;13:253\u201366. https:\/\/doi.org\/10.1515\/jtim-2025-0028.","journal-title":"J Transl Int Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02172-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:17:58Z","timestamp":1783466278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02172-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2172"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02172-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflict of Interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Peking University People\u2019s Hospital (Ref No. 2021PHA154-001).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"254"}}